Research programme: mTORC protein inhibitors - Intellikine/PKD Foundation

Drug Profile

Research programme: mTORC protein inhibitors - Intellikine/PKD Foundation

Latest Information Update: 03 Jun 2016

Price : $50

At a glance

  • Originator Intellikine
  • Developer Intellikine; Takeda America Holdings
  • Class Small molecules
  • Mechanism of Action MTORC1 protein inhibitors; MTORC2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Polycystic kidney disease

Most Recent Events

  • 01 Jan 2012 Intellikine has been acquired and merged into Takeda America Holdings
  • 11 Feb 2011 Preclinical trials in Polycystic kidney disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top